Viridian Therapeutics (VRDN) Prices Upsized Concurrent Public Offerings Totaling $350M

Viridian Therapeutics (VRDN) Prices Upsized Concurrent Public Offerings Totaling $350M Maham Fatima Thu, May 21, 2026 at 8:30 PM GMT+7 2 min read VRDN Viridian Therapeutics Inc. (NASDAQ:VRDN) is one of the best low priced stocks to buy for the next 3 years. On May 6, Viridian Therapeutics announced the pricing of upsized concurrent public offerings totaling $350 million in aggregate gross proceeds. The financing consists of $225 million in 1.75% convertible senior notes due 2032 and an equity offering of 7,352,942 shares of common stock priced at $17.00 per share. Net proceeds are estimated at $334.7 million, with underwriters granted 30-day options to purchase up to an additional $25 million in notes and 1,102,941 shares of common stock.

The convertible notes will be unsecured, senior obligations maturing on May 15, 2032, with interest payable semi-annually. The initial conversion rate is set at 40.5680 shares per $1,000 principal amount, representing an initial conversion price of approximately $24.65 per share and a 45.0% premium over the public equity offering price. Viridian retains the option to redeem the notes on or after May 20, 2030, provided its stock price exceeds 130% of the conversion price for a specified trading duration.

Viridian Therapeutics Inc. (NASDAQ:VRDN) plans to use the net proceeds to fully repay its outstanding debt with Hercules Capital Inc. The remaining capital will fund market expansion studies for its thyroid eye disease franchise, advance early-stage pipeline research, and support general working capital needs.